Latest Administration News

Artrya Limited has converted three US foundation partners into commercial customers, generating its first fee-per-scan revenues, while progressing FDA clearance for its Salix Coronary Flow module and expanding its clinical study network.

Infinity Metals Limited reported a steady cash position of A$2.25 million at the end of December 2025, with operational spending continuing but no new financing activities. The company estimates funding for over five quarters based on current expenditure.

Adheris Health reported a sharp decline in Q2 FY26 revenue but is pushing ahead with leadership changes, cost cuts, and a new digital platform to reshape its future.

Nutritional Growth Solutions reports improved cash flow and cost savings amid leadership changes, setting the stage for renewed growth in FY26.

AKORA Resources has completed a significant trenching program at its Bekisopa iron ore project in Madagascar and submitted a mining permit application under a revitalised regulatory framework, gaining strong government backing.

Viking Mines has entered a binding agreement to acquire six high-grade tungsten projects in Nevada, backed by a strategic investment from American Tungsten Corp and a $4.29 million capital raise. The acquisition marks a significant expansion into the critical US tungsten market amid rising global demand.

Opthea Limited has streamlined its operations with a NASDAQ delisting and completed a strategic review, positioning itself to advance the OPT-302 treatment for LAM with a robust cash position.

Manuka Resources has released an updated 10-year Pre-Feasibility Study for its Cobar Basin projects, revealing a substantial uplift in project economics and a clear path to production by mid-2026.

PentaNet Ltd reported a positive net operating cash flow of A$710,000 for the December 2025 quarter, alongside a strong cash position of A$2.42 million. The company completed its final payment for a 15-year 5G spectrum license while maintaining access to substantial financing facilities.

Kingsrose Mining’s December quarter report reveals steady progress in its Finnmark exploration alliance and a significant permitting hurdle at its Penikat project in Finland. The company maintains a solid cash position as it plans for 2026 drilling campaigns.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.

Neurotech International has secured a Rare Pediatric Disease Designation from the FDA for its lead drug NTI164 targeting Rett syndrome, alongside publishing promising clinical data and raising $8.7 million to fuel further development.